AstraZeneca PLC

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB0009895292
GBP
138.96
36 (34.97%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

3.68 M

Shareholding (Dec 2025)

FII

0.06%

Held by 25 FIIs

DII

99.94%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 218,872 Million ()

stock-summary
P/E

29.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

224.05%

stock-summary
Debt Equity

0.61

stock-summary
Return on Equity

21.94%

stock-summary
Price to Book

6.05

Revenue and Profits:
Net Sales:
11,657 Million
(Quarterly Results - Dec 2025)
Net Profit:
1,751 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
23.96%
0%
23.96%
6 Months
40.36%
0%
40.36%
1 Year
45.2%
0%
45.2%
2 Years
84.42%
0%
84.42%
3 Years
103.75%
0%
103.75%
4 Years
151.28%
0%
151.28%
5 Years
114.74%
0%
114.74%

AstraZeneca PLC for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
15.61%
EBIT Growth (5y)
21.72%
EBIT to Interest (avg)
4.36
Debt to EBITDA (avg)
1.85
Net Debt to Equity (avg)
0.61
Sales to Capital Employed (avg)
0.64
Tax Ratio
16.21%
Dividend Payout Ratio
47.19%
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
12.02%
ROE (avg)
15.16%

Valuation key factors

Factor
Value
P/E Ratio
29
Industry P/E
Price to Book Value
6.33
EV to EBIT
23.78
EV to EBITDA
16.74
EV to Capital Employed
4.65
EV to Sales
5.52
PEG Ratio
1.06
Dividend Yield
214.01%
ROCE (Latest)
19.55%
ROE (Latest)
21.94%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 25 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.33% vs 19.85% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 49.63% vs 51.37% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11,657.30",
          "val2": "11,619.20",
          "chgp": "0.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,342.40",
          "val2": "3,412.20",
          "chgp": "-2.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "363.90",
          "val2": "334.70",
          "chgp": "8.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-42.90",
          "val2": "-78.00",
          "chgp": "45.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,751.30",
          "val2": "1,170.40",
          "chgp": "49.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "189.30%",
          "val2": "136.70%",
          "chgp": "5.26%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 5.33% vs 14.82% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 40.92% vs 14.90% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "44,570.50",
          "val2": "42,316.90",
          "chgp": "5.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "14,794.90",
          "val2": "13,972.30",
          "chgp": "5.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1,013.00",
          "val2": "1,088.60",
          "chgp": "-6.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-669.30",
          "val2": "-2,460.50",
          "chgp": "72.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7,764.70",
          "val2": "5,510.20",
          "chgp": "40.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "238.50%",
          "val2": "236.50%",
          "chgp": "0.20%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
11,657.30
11,619.20
0.33%
Operating Profit (PBDIT) excl Other Income
3,342.40
3,412.20
-2.05%
Interest
363.90
334.70
8.72%
Exceptional Items
-42.90
-78.00
45.00%
Consolidate Net Profit
1,751.30
1,170.40
49.63%
Operating Profit Margin (Excl OI)
189.30%
136.70%
5.26%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is 0.33% vs 19.85% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 49.63% vs 51.37% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
44,570.50
42,316.90
5.33%
Operating Profit (PBDIT) excl Other Income
14,794.90
13,972.30
5.89%
Interest
1,013.00
1,088.60
-6.94%
Exceptional Items
-669.30
-2,460.50
72.80%
Consolidate Net Profit
7,764.70
5,510.20
40.92%
Operating Profit Margin (Excl OI)
238.50%
236.50%
0.20%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 5.33% vs 14.82% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 40.92% vs 14.90% in Dec 2024

stock-summaryCompany CV
About AstraZeneca PLC stock-summary
stock-summary
AstraZeneca PLC
Pharmaceuticals & Biotechnology
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.
Company Coordinates stock-summary
Company Details
1 Francis Crick Avenue , CAMBRIDGE None : CB2 0AA
stock-summary
Tel: 44 20 7304500044 203 7495712
stock-summary
Registrar Details